This content is from: Patents

Federal Circuit says biosimilar applicants can decline patent dance

The Federal Circuit in Amgen v Sandoz was split two ways, holding biosimilar applicants can opt out of the patent dance provisions but must wait for approval before giving 180 days notice of marketing. Applicants and patent owners now face tricky strategic questions

To access our in-house intelligence please request a trial here.

Read this article – and more – for a 30 day period.


Are you already an Managing IP subscriber? Login here


Instant access to all of our content. Membership Options | 30 Day Trial